Immunodynamics of explanted human tumors for immuno‐oncology

Decision making in immuno‐oncology is pivotal to adapt therapy to the tumor microenvironment (TME) of the patient among the numerous options of monoclonal antibodies or small molecules. Predicting the best combinatorial regimen remains an unmet medical need. Here, we report a multiplex functional and dynamic immuno‐assay based on the capacity of the TME to respond to ex vivo stimulation with twelve immunomodulators including immune checkpoint inhibitors (ICI) in 43 human primary tumors. This "in sitro" (in situ/in vitro) assay has the potential to predict unresponsiveness to anti‐PD‐1 mAbs, and to detect the most appropriate and personalized combinatorial regimen. Prospective clinical trials are awaited to validate this in sitro assay.

[1]  Hongyu Zhao,et al.  Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors , 2020, Nature Medicine.

[2]  Xiaozhong Wang,et al.  Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cells , 2020, Nature Communications.

[3]  Peter Schmid,et al.  Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer , 2019, Nature Medicine.

[4]  A. Ribas,et al.  Tumour-intrinsic resistance to immune checkpoint blockade , 2019, Nature Reviews Immunology.

[5]  Hiromasa Morikawa,et al.  PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer , 2019, Proceedings of the National Academy of Sciences.

[6]  P. Linsley,et al.  Renal Cell Carcinoma (RCC) Tumors Display Large Expansion of Double Positive (DP) CD4+CD8+ T Cells With Expression of Exhaustion Markers , 2018, Front. Immunol..

[7]  J. Soria,et al.  Hyperprogressive disease: recognizing a novel pattern to improve patient management , 2018, Nature Reviews Clinical Oncology.

[8]  J. Allison,et al.  Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. , 2018, Cancer discovery.

[9]  C. Klein,et al.  A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small cell lung cancer treated with PD-1 blockade , 2018, Nature Medicine.

[10]  Angela E. Leek,et al.  Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies , 2018, Cancer cell.

[11]  T. Chan,et al.  Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab , 2017, Cell.

[12]  David M. Woods,et al.  Predictors of responses to immune checkpoint blockade in advanced melanoma , 2017, Nature Communications.

[13]  D. Hanahan,et al.  Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma , 2017, Science Translational Medicine.

[14]  Carsten Denkert,et al.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothe , 2017, Advances in anatomic pathology.

[15]  M. Smyth,et al.  Abstract B115: Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease , 2016 .

[16]  Yusuke Nakamura,et al.  Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma , 2016, Oncoimmunology.

[17]  P. Ross-Macdonald,et al.  Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma , 2016, Clinical Cancer Research.

[18]  J. Banchereau,et al.  Immunotherapy: The Path to Win the War on Cancer? , 2015, Cell.

[19]  Jeff Scott.  Renal Cell , 2020, Definitions.

[20]  the original work is properly cited. , 2022 .